GLP-1 and metabolic medicine
GLP-1 drugs and the new science of obesity, diabetes and metabolic disease.
- WikiCagriSema (cagrilintide and semaglutide)CagriSema combines the amylin analogue cagrilintide with semaglutide. Novo Nordisk's REDEFINE results, the miss against tirzepatide and its FDA review.Updated
- WikiEli Lilly and CompanyEli Lilly makes tirzepatide (Mounjaro, Zepbound) and the GLP-1 pill Foundayo, and is developing retatrutide. Its 2026 results, pipeline and pricing.Updated
- WikiNovo NordiskNovo Nordisk is the Danish maker of semaglutide (Ozempic, Wegovy, Wegovy pill). Its GLP-1 history, 2025–2026 results, pipeline and pricing pressures.Updated
- WikiOrforglipron (Foundayo)Orforglipron (Foundayo) is Eli Lilly's once-daily small-molecule GLP-1 pill, FDA-approved for weight management in April 2026. Trial data and pricing.Updated
- WikiRetatrutideRetatrutide is Eli Lilly's investigational GIP, GLP-1 and glucagon triple agonist. Phase 2 and TRIUMPH phase 3 results and its 2027 filing plan.Updated
- WikiSemaglutideSemaglutide (Ozempic, Wegovy, Rybelsus, Wegovy pill) is Novo Nordisk's GLP-1 drug. Its trials, approvals, oral forms, prices and patent status in 2026.Updated
- WikiTirzepatideTirzepatide (Mounjaro, Zepbound) is Eli Lilly's dual GIP/GLP-1 agonist. Its trials, approvals, head-to-head data, sales and pricing as of 2026.Updated
- AnalysisWho gets GLP-1 drugs? The 2026 price and coverage debateGLP-1 prices, Medicare's Bridge, negotiated prices, compounding and generics: the evidence on access in 2026 and the competing views on what comes next.Updated
- AnalysisLifelong GLP-1s? The debate over long-term useWhat happens when people stop GLP-1 drugs, what is known about muscle, nutrition and rare side effects, and the competing views on long-term use.Updated
- ExplainerGLP-1 outcome trials explained: heart, kidney, liver and beyondWhat the big GLP-1 outcome trials (SELECT, FLOW, ESSENCE, SURMOUNT-OSA, SURPASS-CVOT, evoke) found, how to read them, and what regulators approved.Updated
- ExplainerHow GLP-1 drugs workHow incretin hormones like GLP-1 and GIP control insulin and appetite, and how drug designers stretched them into weekly shots, pills and multi-agonists.Updated
- ExplainerObesity as a chronic diseaseWhy WHO and a Lancet Commission now frame obesity as a chronic disease, what "clinical" versus "preclinical" obesity means, and BMI's limits.Updated